Literature DB >> 28640704

Immunotherapy for Brain Tumors.

John H Sampson1, Marcela V Maus1, Carl H June1.   

Abstract

Glioblastoma (GBM) is the most lethal form of brain tumor and remains a large, unmet medical need. This review focuses on recent advances in the neurosciences that converge with the broader field of immuno-oncology. Recent findings in neuroanatomy provide a basis for new approaches of cellular therapies for tumors that involve the CNS. The ultimate success of immunotherapy in the CNS will require improved imaging technologies and methods for analysis of the tumor microenvironment in patients with GBM. It is likely that combinatorial approaches with targeted immunotherapies will be required to exploit the vulnerabilities of GBM and other brain tumors.

Entities:  

Mesh:

Year:  2017        PMID: 28640704     DOI: 10.1200/JCO.2017.72.8089

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  49 in total

Review 1.  Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.

Authors:  William Tomaszewski; Luis Sanchez-Perez; Thomas F Gajewski; John H Sampson
Journal:  Clin Cancer Res       Date:  2019-02-25       Impact factor: 12.531

2.  EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma.

Authors:  Zhenyi An; Christiane B Knobbe-Thomsen; Xiaohua Wan; Qi Wen Fan; Guido Reifenberger; William A Weiss
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

3.  Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients.

Authors:  Caressa Y Hui; Soumon Rudra; Sirui Ma; Jian L Campian; Jiayi Huang
Journal:  J Neurooncol       Date:  2019-03-12       Impact factor: 4.130

4.  Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain.

Authors:  Benjamin A Plog; Humberto Mestre; Genaro E Olveda; Amanda M Sweeney; H Mark Kenney; Alexander Cove; Kosha Y Dholakia; Jeffrey Tithof; Thomas D Nevins; Iben Lundgaard; Ting Du; Douglas H Kelley; Maiken Nedergaard
Journal:  JCI Insight       Date:  2018-10-18

Review 5.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 6.  Adoptive Cell Therapy in Treating Pediatric Solid Tumors.

Authors:  Mekdem Tesfaye; Barbara Savoldo
Journal:  Curr Oncol Rep       Date:  2018-08-01       Impact factor: 5.075

7.  Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.

Authors:  Vassilis Genoud; Eliana Marinari; Sergey I Nikolaev; John C Castle; Valesca Bukur; Pierre-Yves Dietrich; Hideho Okada; Paul R Walker
Journal:  Oncoimmunology       Date:  2018-09-05       Impact factor: 8.110

8.  Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.

Authors:  Jonathan B Lamano; Jason Balquidera Lamano; Yuping D Li; Joseph D DiDomenico; Winward Choy; Dorina Veliceasa; Daniel E Oyon; Shayan Fakurnejad; Leonel Ampie; Kartik Kesavabhotla; Rajwant Kaur; Gurvinder Kaur; Dauren Biyashev; Dusten J Unruh; Craig M Horbinski; C David James; Andrew T Parsa; Orin Bloch
Journal:  Clin Cancer Res       Date:  2019-03-01       Impact factor: 12.531

9.  Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.

Authors:  Nan Ji; Yang Zhang; Yunpeng Liu; Jian Xie; Yi Wang; Shuyu Hao; Zhixian Gao
Journal:  JCI Insight       Date:  2018-05-17

Review 10.  Immunotherapy in CNS cancers: the role of immune cell trafficking.

Authors:  Nivedita M Ratnam; Mark R Gilbert; Amber J Giles
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.